Hayashi, Tetsuya
Nakamae, Hirohisa http://orcid.org/0000-0003-4203-990X
Takeda, Shinichi
Nakashima, Yasuhiro
Koh, Hideo
Nishimoto, Mitsutaka
Okamura, Hiroshi
Nanno, Satoru
Makuuchi, Yosuke
Kuno, Masatomo
Nakamae, Mika
Hirose, Asao
Hino, Masayuki
Article History
Received: 23 April 2021
Revised: 13 July 2021
Accepted: 14 July 2021
First Online: 26 July 2021
Declarations
:
: Dr. Hayashi reports honoraria from MSD K.K. and Kyowa Kirin Co., Ltd. (none of which are related to the submitted work). Dr. Hirohisa Nakamae reports grants from Novartis Pharma K.K., honoraria from Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K., Celgene Corporation, Kyowa Kirin Co., Ltd., and Nippon Shinyaku Co., Ltd.; and an advisory board fee from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Pfizer Japan Inc. (none of which are related to the submitted work). Dr. Nakashima reports grants from Eisai Co., Ltd., Celgene Corporation, and Novartis Pharma K.K., honoraria from Eisai Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K., and Kyowa Kirin Co., Ltd., and an advisory fee from Novartis Pharma K.K. (none of which are related to the submitted work). Dr. Koh reports grants from Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, and Takeda Pharmaceutical Co., Ltd., honoraria from MSD K.K., Takeda Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd., an advisory board fee from Takeda Pharmaceutical Co., Ltd., and a consulting fee from MSD K.K. (none of which are related to the submitted work). Dr. Nishimoto reports honoraria from Kyowa Kirin Co., Ltd. (none of which are related to the submitted work). Dr. Okamura reports honoraria from Eisai Co., Ltd. and Nippon Shinyaku Co., Ltd. (none of which are related to the submitted work). Dr. Nanno reports honoraria from Eisai Co., Ltd. (none of which are related to the submitted work). Dr. Mika Nakamae reports honoraria from Novartis Pharma K.K. (none of which are related to the submitted work). Dr. Hino reports grants from Pfizer Japan Inc., MSD K.K., and Novartis Pharma K.K., honoraria from MSD K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Celgene Corporation, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., and Pfizer Japan Inc., an advisory board fee from Pfizer Japan Inc., and a consulting fee from Kyowa Kirin Co., Ltd. (none of which are related to the submitted work). All the authors (our institution) report grants from MSD K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma, Ltd., Pfizer Japan Inc., and Sumitomo Dainippon Pharma Co., Ltd. (none of which are related to the submitted work).